Idiopathic Granulomatous Mastitis as a Benign Condition Mimicking Inflammatory Breast Cancer: Current Status, Knowledge Gaps and Rationale for the GRAMAREG Study (EUBREAST-15)

Idiopathic granulomatous mastitis (IGM) is a rare, benign inflammatory breast condition often mistaken for inflammatory breast cancer and, therefore, requires a biopsy for accurate diagnosis. Although not cancerous, IGM can cause emotional distress because of severe pain and ensuing breast deformity...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 16; no. 19; p. 3387
Main Authors Krawczyk, Natalia, Kühn, Thorsten, Ditsch, Nina, Hartmann, Steffi, Gentilini, Oreste Davide, Lebeau, Annette, de Boniface, Jana, Hahn, Markus, Çakmak, Güldeniz Karadeniz, Alipour, Sadaf, Bjelic-Radisic, Vesna, Kolberg, Hans-Christian, Reimer, Toralf, Gasparri, Maria Luisa, Tauber, Nikolas, Neubacher, Melissa, Banys-Paluchowski, Maggie
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 03.10.2024
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Idiopathic granulomatous mastitis (IGM) is a rare, benign inflammatory breast condition often mistaken for inflammatory breast cancer and, therefore, requires a biopsy for accurate diagnosis. Although not cancerous, IGM can cause emotional distress because of severe pain and ensuing breast deformity. Differentiating IGM from other breast inflammations caused by infections is essential. IGM mostly affects premenopausal women and is potentially associated with recent pregnancies and breastfeeding. The risk factors, including smoking and contraceptive use, have inconsistent associations. Steroid responses suggest an autoimmune component, though specific markers are lacking. We performed a narrative review on potential risk factors, diagnostics, and therapy of IGM. Diagnostics and clinical management of IGM are challenging. The treatment options include NSAIDs, steroids, surgery, antibiotics, immunosuppressants, prolactin suppressants, and observation, each with varying effectiveness and side effects. Current IGM treatment evidence is limited, based on case reports and small series. There is no consensus on the optimal management strategy for this disease. The GRAMAREG study by the EUBREAST Study Group aims to collect comprehensive data on IGM to improve diagnostic and treatment guidelines. By enrolling patients with confirmed IGM, the study seeks to develop evidence-based recommendations, enhancing patient care and understanding of this condition.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16193387